Estrogen/EGF receptor interactions in breast cancer: rationale for new therapeutic combination strategies
Estrogen/EGF receptor interactions in breast cancer: rationale for new therapeutic combination strategies
复制标题
DOI：
10.1016/j.biopha.2003.09.006
复制
发表时间：
2003-12-01
影响因子：
7.5
通讯作者：
Lichtner, RB
中科院分区：
文献类型：
--
作者：
Lichtner, RB
在雌激素受体（ER）阳性的人乳腺癌的治疗中，抗雌激素三苯氧胺的治疗已经得到很好的确立。然而，激素抵抗的发展是乳腺癌进展对抗内分泌治疗的重要因素。EGF受体（EGFR）的存在与抗雌激素治疗缺乏反应相关。EGFR不仅参与肿瘤细胞生长、存活信号传导、细胞迁移、转移形成和血管生成，而且似乎赋予肿瘤细胞对抗激素的降低的应答。同时抑制雌激素和EGF的受体可能是改善乳腺癌治疗所必需的。(C)2003年，Elsevier SAS科学与医学版。All rights reserved.
In the therapy of estrogen receptor (ER) positive human mammary carcinomas, the treatment with the antiestrogen tamoxifen has been well established. However, the development of hormone resistance is an important factor in breast cancer progression against endocrine therapy. The presence of the receptor for EGF (EGFR) correlates with lack of response towards antiestrogen therapy. The EGFR is not only involved in tumor cell growth, survival signaling, cell migration, metastasis formation and angiogenesis, but also seems to confer reduced responses of tumor cells towards anti-hormones. Concomitant inhibition of both, the receptors for estrogen and EGF may be necessary to improve breast cancer therapy. (C) 2003 Editions scientifiques et medicales Elsevier SAS. All rights reserved.